Epidermal Growth Factor Receptor in Ovarian Tumours
Author Information
Author(s): S.C. Henzen-Logmans, E.M.J.J. Berns, J.G.M. Klijn, M.E.L. van der Burg, J.A. Foekens
Primary Institution: Dr Daniel den Hoed Cancer Center
Hypothesis
What is the correlation between immunohistochemistry and ligand binding assay for EGFR in ovarian tumours?
Conclusion
The study found a significant correlation between EGFR detection methods, with 77% of adenocarcinoma samples testing positive for EGFR.
Supporting Evidence
- 77% of adenocarcinoma samples stained positive for EGFR using immunohistochemistry.
- A significant correlation was found between the percentage of stained tumor cells and EGFR levels measured by ligand binding assay.
- EGFR was detected in 66% of the adenocarcinomas analyzed with ligand binding assay.
Takeaway
This study looked at a protein called EGFR in ovarian tumors to see how well two different testing methods worked. They found that most tumors had this protein.
Methodology
The study used immunohistochemistry and ligand binding assays to analyze EGFR in ovarian tumor samples.
Limitations
The study did not find amplification of the EGFR gene in any of the tumors, which may limit the understanding of its role in ovarian cancer.
Participant Demographics
The study included 128 tumors from patients with various types of ovarian cancer, with a mean age of 58 years.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website